Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 1, 1999The Annual Review of Pharmacology and Toxicology

Cyclins and Cell Cycle Checkpoints

View Full Paper
Ask AI
Bookmark
Share

Authors

DJD. Gale JohnsonMayo Clinic HospitalMWMark J. WalkerThe University of Queensland

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Johnson et al. (1999) studied this question.

synapsesocial.com/papers/6a613aa8dcbd73a1130a402fhttps://doi.org/10.1146/annurev.pharmtox.39.1.295
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1E2F-4, a new member of the E2F transcription factor family, interacts with p107.1994 · 331 citations
  2. 2A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.1995 · 482 citations
  3. 3A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma1995 · 1,159 citations
  4. 4A Syndrome of Multiorgan Hyperplasia with Features of Gigantism, Tumorigenesis, and Female Sterility in p27 -Deficient Mice1996 · 1,480 citations
  5. 5Cyclin D1 Is Dispensable for G 1 Control in Retinoblastoma Gene-Deficient Cells Independently of cdk4 Activity1995 · 368 citations